Decibel Therapeutics, Inc. Stock Price, News & Analysis

Decibel Therapeutics (Nasdaq: DBTX) announced its participation in the 45th Annual MidWinter Meeting of the Association for Research in Otolaryngology, running from February 5–9, 2022. The company will present findings on its investigational gene therapies, DB-OTO and AAV.104, aimed at restoring hearing in patients with specific gene mutations. The presentations include two podium talks and two virtual posters, highlighting advancements in treatments for congenital hearing loss and auditory processing disorders.

Decibel Therapeutics (Nasdaq: DBTX) announced that its CEO, Laurence Reid, will participate in a fireside chat at the H.C. Wainwright BioConnect Conference. The chat will be available for on-demand viewing starting January 10, 2022, at 7:00 am ET. Interested viewers can access the webcast through Decibel's Investors section on their website, with an archived replay available for 90 days post-event.

Decibel Therapeutics focuses on innovative treatments for hearing and balance disorders, utilizing advanced gene therapies and a proprietary platform.

Decibel Therapeutics (Nasdaq: DBTX) announced the appointments of Alison Finger, MBA, and Saraswathy Nochur, Ph.D., to its Board of Directors on December 6, 2021. CEO Laurence Reid highlighted their extensive biopharma experience as crucial for Decibel’s anticipated growth and regulatory affairs. The company also noted the departure of Christine Poon from the Board as of December 3, 2021. Finger and Nochur's backgrounds in commercial strategy and regulatory affairs are expected to enhance Decibel's capabilities in developing transformative treatments for hearing and balance disorders.

Decibel Therapeutics (Nasdaq: DBTX) has announced the extension of its collaboration with Regeneron to develop gene therapies for congenital hearing loss, now running until November 15, 2023. Decibel will receive a $10 million extension payment in Q4 2022. The lead product candidate, DB-OTO, aims to restore hearing in individuals with profound hearing loss due to otoferlin gene mutations, with a Phase 1/2 clinical trial expected to begin in 2022. The partnership enhances Decibel's access to Regeneron's advanced genetic technologies and support for their ongoing gene therapy programs.

Decibel Therapeutics (Nasdaq: DBTX) announced significant progress in its gene therapy pipeline aimed at treating hearing loss. It received Orphan Drug and Rare Pediatric Disease designations for DB-OTO, targeting otoferlin-related congenital hearing loss. The company is on track to submit an IND for DB-OTO and report interim results for the DB-020 trial by mid-2022. Additionally, Decibel launched the AAV.104 program to restore hearing in patients with stereocilin gene mutations, potentially benefiting approximately 70,000 individuals across the U.S. and Europe.

BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX) announced its participation in the Barclays Gene Editing & Gene Therapy Summit on November 15, 2021. CEO Laurence Reid, Ph.D., will engage in a fireside chat at 3:30 pm ET and a panel discussion at 4:45 pm ET focused on regulatory challenges. A live webcast of the chat will be accessible on the company’s website, with an archived replay available for 90 days post-event. Decibel Therapeutics is dedicated to developing transformative treatments for hearing and balance disorders.

Decibel Therapeutics (Nasdaq: DBTX) announced that its CEO, Laurence Reid, will participate in a fireside chat at the Jefferies Gene Therapy/Editing Summit on October 27, 2021, at 10:30 am ET. The session will be available for live streaming on Decibel’s website, with an archived replay accessible for 90 days post-event. Decibel is focused on innovative treatments for hearing and balance disorders and has a promising pipeline, including the lead program DB-OTO, targeting congenital hearing loss.

Decibel Therapeutics (Nasdaq: DBTX) announced the publication of findings from a study on noise-related inner ear damage, conducted in collaboration with the University of Maryland School of Medicine and the Karolinska Institute. The study generated a comprehensive gene expression atlas across inner ear cell types, providing a foundational dataset for future research. Decibel's platform integrates gene expression data and bioinformatics to address the unmet needs in hearing and balance therapies. This significant advancement aims to identify new therapeutics for inner ear damage.

Decibel Therapeutics (Nasdaq: DBTX) has received Orphan Drug and Rare Pediatric Disease Designations from the FDA for its lead gene therapy candidate, DB-OTO, aimed at treating otoferlin-related congenital hearing loss. These designations validate the urgent need for innovative treatments in this area and provide Decibel with potential benefits like market exclusivity and tax credits. DB-OTO, developed in collaboration with Regeneron Pharmaceuticals, is designed to restore hearing in patients with profound loss due to otoferlin gene mutations and is expected to enter clinical trials in 2022.